EE151 Cost-Minimization of Lorlatinib Versus Alectinib for First Line Treatment for Treatment of Alk-Positive Non–Small-Cell Lung Cancer from the Brazilian Private Healthcare System Perspective

Senna, T. ; Alexandre, R.F. ; Almeida, P. ; Sebastião, M. ; Ferreira, P.

Value in health, 2023-06, Vol.26 (6), p.S87-S87 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível